| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.everestorganicsltd.com | |
| Market Cap | 78.37 Cr. | |
| Enterprise Value(EV) | 116.30 Cr. | 2022-12 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -0.01 | Trailing Twelve Months Ending 2022-12 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-12 |
| Industry PE | 32.00 | Trailing Twelve Months Ending 2022-12 |
| Book Value / Share | 57.63 | Trailing Twelve Months Ending 2022-12 |
| Price to Book Value | 1.70 | Calculated using Price: 97.96 |
| Dividend Yield | 0.51 | Period Ending 2022-03 |
| No. of Shares Subscribed | 0.80 Cr. | 8,000,000 Shares |
| FaceValue | 10 | |
| Company Profile | ||
| The company's facilities comply to GMP standards and is certified by the Drug Control Authority of the Government of Andhra Pradesh, India. It supply products to major multinational companies abroad, prominent well established formulation companies in India, Europe, USA, Far East and the Middle East, and also to Latin / Central / South American Countries. The company also provides adequate technical & documentary support for their products and its products comply to various pharmacopial standards like BP, USP, EP and IP Standards as desired by the customer. | ||
| 1 Day |
|
-3.42% |
| 1 Week |
|
-3.83% |
| 1 Month |
|
-1.02% |
| 3 Month |
|
-22.25% |
| 6 Month |
|
-25.09% |
| 1 Year |
|
-45.04% |
| 2 Year |
|
-57.35% |
| 5 Year |
|
-11.36% |
| 10 Year |
|
| 9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | 23.31 | 33.19 | 3.06 | 12.25 | 9.86 | 33.63 | 36.22 | 33.96 | 2.45 | |
| Return on Capital Employed (%) | 13.82 | 15.84 | 8.90 | 13.55 | 13.80 | 35.30 | 35.22 | 33.76 | 6.25 | |
| Return on Assets (%) | 1.42 | 2.50 | 0.25 | 1.67 | 1.90 | 7.45 | 9.58 | 10.73 | 0.73 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12* Rs. Cr. |
| Shh. Funds | 4 | 6 | 6 | 16 | 19 | 26 | 34 | 47 | 47 | 46 | |
| Non Curr. Liab. | 10 | 11 | 14 | 7 | 8 | 10 | 12 | 11 | 19 | 18 | |
| Curr. Liab. | 51 | 50 | 56 | 63 | 67 | 71 | 74 | 77 | 113 | 133 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 65 | 67 | 76 | 86 | 94 | 107 | 120 | 135 | 178 | 198 | |
| Non Curr. Assets | 25 | 25 | 29 | 37 | 36 | 40 | 41 | 46 | 60 | 66 | |
| Curr. Assets | 41 | 42 | 47 | 49 | 58 | 67 | 79 | 89 | 118 | 132 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 65 | 67 | 76 | 86 | 94 | 107 | 120 | 135 | 178 | 198 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
| Net Sales | 96 | 106 | 99 | 107 | 112 | 156 | 167 | 182 | 200 | 187 | |
| Other Income | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 7 | |
| Total Income | 97 | 107 | 100 | 108 | 113 | 156 | 169 | 183 | 202 | 194 | |
| Total Expenditure | -91 | -98 | -94 | -101 | -105 | -138 | -148 | -159 | -194 | -187 | |
| PBIDT | 6 | 8 | 6 | 7 | 8 | 18 | 21 | 24 | 9 | 7 | |
| Interest | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | |
| Depreciation | -2 | -3 | -3 | -2 | -3 | -3 | -3 | -3 | -4 | -4 | |
| Taxation | 0 | 0 | 0 | 0 | -1 | -5 | -3 | -4 | -1 | 0 | |
| Exceptional Items | -1 | -1 | |||||||||
| PAT | 1 | 2 | 0 | 1 | 2 | 8 | 11 | 14 | 1 | 0 | |
| Adjusted EPS | 1 | 2 | 1 | 2 | 2 | 9 | 14 | 17 | 1 | 0 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | 7 | 1 | 4 | 7 | 10 | 5 | 9 | 10 | 14 | 14 | |
| Cash Fr. Inv. | -4 | -3 | -3 | -7 | -8 | -4 | -5 | -6 | -12 | -17 | |
| Cash Fr. Finan. | -3 | 2 | -2 | 0 | -2 | 0 | -3 | -3 | -2 | 2 | |
| Net Change | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | -1 | |
| Cash & Cash Eqvt | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 1 |
|
Thu, 23 Mar 2023
Disclosure Under Regulation 29 (2) Of SEBI (Substantial Acquisition Of Shares And Takeover) Regulations 2011 And Regulation 7 (2) Read With Regulation 6(2) Of SEBI (Prohibition Of Insider Trading) Regulations 2015 With reference to the captioned subject please find enclosed herewith the disclosure received from the acquirer Dr. Srikakarlapudi Krishnaveni one of the Promoters of the Company through transmission of shares in Form 29(2) under Regulation 29 of SEBI (Substantial Acquisition of Shares and Takeover) Regulations 2011 and Form C under Regulation 7(2) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations 2015.Kindly take the above information on record. |
|
Thu, 23 Mar 2023
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Dr Srikakarlapudi Krishnaveni |
|
Wed, 15 Feb 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication With reference to the captioned subject and pursuant to Regulation 47 of Securities Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations 2015 we hereby inform you that the Company has published the Un-Audited Financial Results of the Company for the third quarter ended December 31 2022 approved by the Board of Directors at its Meeting held on Tuesday the 14th day February 2023 in Financial Express (English Newspaper) and Nava Telangana (Telugu Newspaper) on 15.02.2023. The said publication is enclosed herewith.Kindly take the above information on record. |
| Tue, 28 Mar 2023 |
Close Crossing Last Week Low
|
Close Crossing Last Month Close from Above
|
Closing Below Previous Low
|
Making Lower Lows for 3 days
|
Close Within 52 Week Low Zone
|
Equities
M.F.
Sectors